Takahiro Sasaki1, Hiroaki Katagi1, Stewart Goldman2, Oren J Becher2,3, Rintaro Hashizume1,3. 1. Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Division of Hematology, Oncology and Stem Cell Transplantation in the Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood brain tumor and the majority of patients die within 2 yr after initial diagnosis. Factors that contribute to the dismal prognosis of these patients include the infiltrative nature and anatomic location in an eloquent area of the brain, which precludes total surgical resection, and the presence of the blood-brain barrier (BBB), which reduces the distribution of systemically administered agents. Convection-enhanced delivery (CED) is a direct infusion technique to deliver therapeutic agents into a target site in the brain and able to deliver a high concentration drug to the infusion site without systemic toxicities. OBJECTIVE: To assess the efficacy of enhancer of zeste homolog-2 (EZH2) inhibitor by CED against human DIPG xenograft models. METHODS: The concentration of EZH2 inhibitor (EPZ-6438) in the brainstem tumor was evaluated by liquid chromatography-mass spectrometry (LC/MS). We treated mice-bearing human DIPG xenografts with EPZ-6438 using systemic (intraperitoneal) or CED administration. Intracranial tumor growth was monitored by bioluminescence image, and the therapeutic response was evaluated by animal survival. RESULTS: LC/MS analysis showed that the concentration of EPZ-6438 in the brainstem tumor was 3.74% of serum concentration after systemic administration. CED of EPZ-6438 suppressed tumor growth and significantly extended animal survival when compared to systemic administration of EPZ-6438 (P = .0475). CONCLUSION: Our results indicate that CED of an EZH2 inhibitor is a promising strategy to bypass the BBB and to increase the efficacy of an EZH2 inhibitor for the treatment of DIPG.
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood brain tumor and the majority of patients die within 2 yr after initial diagnosis. Factors that contribute to the dismal prognosis of these patients include the infiltrative nature and anatomic location in an eloquent area of the brain, which precludes total surgical resection, and the presence of the blood-brain barrier (BBB), which reduces the distribution of systemically administered agents. Convection-enhanced delivery (CED) is a direct infusion technique to deliver therapeutic agents into a target site in the brain and able to deliver a high concentration drug to the infusion site without systemic toxicities. OBJECTIVE: To assess the efficacy of enhancer of zeste homolog-2 (EZH2) inhibitor by CED against human DIPG xenograft models. METHODS: The concentration of EZH2 inhibitor (EPZ-6438) in the brainstem tumor was evaluated by liquid chromatography-mass spectrometry (LC/MS). We treated mice-bearing human DIPG xenografts with EPZ-6438 using systemic (intraperitoneal) or CED administration. Intracranial tumor growth was monitored by bioluminescence image, and the therapeutic response was evaluated by animal survival. RESULTS: LC/MS analysis showed that the concentration of EPZ-6438 in the brainstem tumor was 3.74% of serum concentration after systemic administration. CED of EPZ-6438 suppressed tumor growth and significantly extended animal survival when compared to systemic administration of EPZ-6438 (P = .0475). CONCLUSION: Our results indicate that CED of an EZH2 inhibitor is a promising strategy to bypass the BBB and to increase the efficacy of an EZH2 inhibitor for the treatment of DIPG.
Authors: Antoine Italiano; Jean-Charles Soria; Maud Toulmonde; Jean-Marie Michot; Carlo Lucchesi; Andrea Varga; Jean-Michel Coindre; Stephen J Blakemore; Alicia Clawson; Benjamin Suttle; Alice A McDonald; Mark Woodruff; Scott Ribich; Eric Hedrick; Heike Keilhack; Blythe Thomson; Takashi Owa; Robert A Copeland; Peter T C Ho; Vincent Ribrag Journal: Lancet Oncol Date: 2018-04-09 Impact factor: 41.316
Authors: A Charlotte P Sewing; Viola Caretti; Tonny Lagerweij; Pepijn Schellen; Marc H A Jansen; Dannis G van Vuurden; Sander Idema; Carla F M Molthoff; W Peter Vandertop; Gertjan J L Kaspers; David P Noske; Esther Hulleman Journal: J Neurosci Methods Date: 2014-09-27 Impact factor: 2.390
Authors: Jeffrey N Bruce; Robert L Fine; Peter Canoll; Jonathan Yun; Benjamin C Kennedy; Steven S Rosenfeld; Stephen A Sands; Krishna Surapaneni; Rose Lai; Candix L Yanes; Emilia Bagiella; Robert L DeLaPaz Journal: Neurosurgery Date: 2011-12 Impact factor: 4.654
Authors: O van Tellingen; B Yetkin-Arik; M C de Gooijer; P Wesseling; T Wurdinger; H E de Vries Journal: Drug Resist Updat Date: 2015-03-06 Impact factor: 18.500
Authors: Quintino Giorgio D'Alessandris; Simone Pacioni; Vittorio Stumpo; Mariachiara Buccarelli; Liverana Lauretti; Martina Giordano; Rina Di Bonaventura; Maurizio Martini; Luigi M Larocca; Stefano Giannetti; Nicola Montano; Maria Laura Falchetti; Lucia Ricci-Vitiani; Roberto Pallini Journal: Biomed Res Int Date: 2021-03-08 Impact factor: 3.411
Authors: Dennis S Metselaar; Aimée du Chatinier; Iris Stuiver; Gertjan J L Kaspers; Esther Hulleman Journal: Front Oncol Date: 2021-04-01 Impact factor: 6.244